The FDA recently approved the fourth biosimilar to Genentech’s Avastin, Vegzelma (bevacizumab-adcd) from Celltrion USA. Vegzelma is an infused therapy administered by a healthcare professional.
The FDA recently approved a novel infused therapy, Terlivaz (terlipressin) from Mallinckrodt, with an indication for hepatorenal syndrome (HRS) with rapid reduction in kidney function. There are
The FDA recently approved a BLA for Rolvedon (eflapegrastim-xnst) from Spectrum Pharmaceuticals. It has an indication to decrease the incidence of infection, as manifested by febrile
The FDA has just approved an oral suspension therapy, Relyvrio from Amylyx Pharmaceuticals, for ALS (amyotrophic lateral sclerosis or Lou Gehrig’s disease). Relyvrio joins a surprisingly
A few weeks ago, a press release from Shields Health announced that it had obtained accreditation from URAC…… not as a dispensing specialty pharmacy but,
We reviewed a report from the Office of Disease Prevention and Health Promotion, a part of the U.S. Department of Health and Human Services some
It’s been a rocky road for CVS of late. In July, CVS was assessed a multi-million $ fine in an arbitration case filed by a small
We’ve written numerous times about value-based contracting (VBC)….. including earlier this week. When it emerged a few years ago there was much hope that VBC
Value Based Contracting….. the great hope for fixing many of the disparities in access and payment for pharmaceuticals, especially those that cost a boat load of
Several recent reports have touched on biosimilars and today we’ll offer up some new data that shows how pricing is being impacted. A new university
